CYP2E1: A Potential Drug Target and Biomarker (G1571)

Target Name: CYP2E1

NCBI ID: G1571

CYP2E1

CYP2E1: A Potential Drug Target and Biomarker

CYP2E1 (microsomal monoxygenase), a gene encoding a protein involved in the metabolism of many drugs, has been identified as a potential drug target or biomarker. The protein encoded by the CYP2E1 gene has been shown to interact with a variety of drugs, including many statins, benzodiazepines, and opioids.

The CYP2E1 gene is located on chromosome 6 and encodes a protein of 25 kDa. The protein is expressed in many tissues and cells of the body, including the brain, heart, liver, and kidneys. It is primarily localized to the mitochondria, where it is involved in the final step of the citric acid cycle, also known as the Krebs cycle or TCA cycle.

The function of CYP2E1 is to convert farnesylated aromatic acids, which are non-volatile fatty acids found in cell membranes, to their more compact form, known as 2-fold intermediates. This conversion is a critical step in the citric acid cycle and is rate-limiting for the production of ATP, the energy currency of the cell.

CYP2E1 has been shown to play a role in the metabolism of many drugs, including many statins, benzodiazepines, and opioids. For example, studies have shown that CYP2E1 is a strong predictor of the metabolism of statins and that it is expressed in the livers of statin-treated patients. Additionally, CYP2E1 has been shown to be a good predictor of the metabolism of opioids and that it is expressed in the brains of opioid-trained rats.

CYP2E1 is also involved in the metabolism of many other drugs, including many psychiatric and neurological drugs, such as antidepressants, antipsychotics, and tranquilizers. For example, studies have shown that CYP2E1 is a strong predictor of the metabolism of antidepressants and that it is expressed in the brains of patients treated with these drugs.

In addition to its role in drug metabolism, CYP2E1 is also involved in the regulation of cellular processes that are important for many cellular functions, including cell survival, growth, and division. For example, studies have shown that CYP2E1 is involved in the regulation of cell apoptosis, which is a natural process that helps the body eliminate damaged or unneeded cells.

Given its involvement in so many cellular processes, CYP2E1 is a promising target for drug development. Many drugs that affect CYP2E1 activity have been identified and are currently in development. For example, a number of studies have shown that inhibitors of CYP2E1 can be effective in treating various diseases, including cardiovascular disease, neurodegenerative diseases, and addiction.

In addition to its potential as a drug target, CYP2E1 is also a potential biomarker for a number of diseases. For example, studies have shown that CYP2E1 levels are elevated in the brains of individuals with certain psychiatric and neurological disorders, such as depression and Alzheimer's disease. Additionally, CYP2E1 levels have been shown to be elevated in the livers of individuals with certain diseases, such as cirrhosis and nonalcoholic steatohepatitis.

Given its potential as a drug target and biomarker, CYP2E1 is an important molecule that is being targeted by drug developers. Further research is needed to fully understand the role of CYP2E1 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Cytochrome P450 Family 2 Subfamily E Member 1

Functions: A cytochrome P450 monooxygenase involved in the metabolism of fatty acids (PubMed:10553002, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10553002, PubMed:18577768). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates fatty acids specifically at the omega-1 position displaying the highest catalytic activity for saturated fatty acids (PubMed:10553002, PubMed:18577768). May be involved in the oxidative metabolism of xenobiotics (Probable)

The "CYP2E1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2E1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets